IMMUNOHISTOCHEMISTRY OF PROSTATE SPECIFIC ANTIGEN IN ADVANCED STAGE PROSTATE CARCINOMA.  INMUNOHISTOQUÍMICA DEL ANTÍGENO PROSTÁTICO ESPECÍFICO EN ESTADÍOS AVANZADOS DEL CARCINOMA DE PRÓSTATA

El cáncer de próstata es la malignidad más frecuente en los seres humanos en la actualidad. Los estudios post mortem hacen una estimación que el carcinoma de próstata (PCa) se propagará en 25% de los hombres con enfermedad establecida histológica-mente. Material y método: Se ha hecho una investigación retrospectiva sobre la expresión inmune histoquímica de antígeno prostático específico (PSA) en 84 pacientes ingresados en el hospital con sospecha clínica de cáncer de próstata. Fueron examinadas portaobjetos del archivo de biopsia de resección transuretral, biopsia por punción con aguja hueca y cirugía abierta. Portaobjetos tenidos fueron utilizados para el diagnóstico patológico y para la puntuacion de Gleason. Portaobjetos adicionales fueron tenidos para antígeno prostático específico y la reacción final del producto fue estimado en negativo (0), bajo/moderado positivo (+1) y positivo intenso (+2). Resultados: Hiperplasia benigna próstata fue encontrado en 14 casos, y todos mostraron una reacción moderada /intensa para el antígeno prostático específico. Hiperplasia asociada basal de células fue siempre negativa. Carcinoma fue encontrado en 68 pacientes. La reacción inmune para antígeno prostático específico fue positiva en 88.2% casos, y encontramos una relación directa entre la intensidad de la reacción y la puntuacion de Gleason. Todas las carcinomas uroteliales y pequeñas fueron negativas. La reacción PSA ha detectado 39.68 % de los casos con invasión perineural en comparación con solamente 23.8% encontrado en los portaobjetos tenidos hematoxilina-eosina (H&E). La expresión inmune antígeno prostático específico no discrimina entre lesiones benignas atípicas y el carcinoma bien diferenciados. Conclusión: Se concluye que la reacción inmune antígeno prostático específico ayuda mucho para el diagnóstico diferenciado, detección de la invasión perineural, y el metástasis ganglionar. Prostate cancer is the most frequent malignancy in human nowadays. Postmortem studies estimate that prostate carcinoma (PCa) will spread in only 25% of men with histologically defined disease. Material and method: It was retrospectively investigated the immunohistochemical expression of prostate-specific antigen (PSA) in 84 patients admitted with clinical suspicion of prostate cancer. Slides were performed from archive biopsies taken by transurethral resection, core biopsy and open surgery. Routine stained slides were used for the pathologic diagnosis and Gleason score. Additional slides were stained for PSA, and the final reaction product was estimated as negative (0), weak/moderate positive (+1), and intense positive (+2). Results: Benign prostate hyperplasia was found in 14 cases, and all showed moderate/intense reaction for PSA. Associated basal cell hyperplasia was always negative. Carcinoma was found in 68 patients. The immunoreaction for PSA was positive in 88.2% cases, and we found a direct relationship between the intensity of the reaction and Gleason score. All urothelial and small carcinomas were negative. PSA immunoreaction detected 39.68% cases with perineural invasion as compared with only 23.8% found on hematoxylin-eosin (H&E) stained slides. PSA immunoexpression does not discriminate between atypical benign lesions and well-differentiated carcinoma. Conclusion: It is concluded that PSA immunoreaction is helpful for the differential diagnosis, detection of the perineural invasion, and lymph node metastases.

Download Full-text

Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia

Disease Markers ◽

10.1155/2016/8915809 ◽

2016 ◽

Vol 2016 ◽

pp. 1-12 ◽

Cited By ~ 12

Author(s):

Chun-Jen Hsiao ◽

Tzong-Shin Tzai ◽

Chein-Hung Chen ◽

Wen-Horng Yang ◽

Chung-Hsuan Chen

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Benign Prostate Hyperplasia ◽

Clinical Sample ◽

Specific Antigen ◽

Ion Accumulation ◽

Detection Sensitivity ◽

Prostate Hyperplasia ◽

Liquid Chromatography Tandem Mass ◽

Benign Prostate

Glycans of prostate-specific antigen (PSA) in prostate cancer were found to be different from that in benign disease. It is difficult to analyze heterogeneous PSA glycoforms in each individual specimen because of low protein abundance and the limitation of detection sensitivity. We developed a method for prostate cancer diagnosis based on PSA glycoforms. Specific glycoforms were screened in each clinical sample based on liquid chromatography-tandem mass spectrometry with ion accumulation. To look for potential biomarkers, normalized abundance of each glycoform in benign prostate hyperplasia (BPH) and in prostate cancer was evaluated. The PSA glycoform, Hex5HexNAc4NeuAc1dHex1, and monosialylated, sialylated, and unfucosylated glycoforms differed significantly between the prostate cancer and BPH samples. The detection sensitivity (87.5%) and specificity (60%) for prostate cancer identification are higher than those of the serum PSA marker. As low as 100 amol PSA could be detected with the ion accumulation method which has not been reported before. The improved detection specificity can help reduce unnecessary examinations.

Download Full-text

ETS-related gene(ERG) expression as a predictor of oncological outcomes in patients with high-grade prostate cancer treated with primary androgen deprivation therapy: a cohort study

BMJ Open ◽

10.1136/bmjopen-2018-025161 ◽

2019 ◽

Vol 9 (3) ◽

pp. e025161

Author(s):

Mark Rezk ◽

Ashish Chandra ◽

Daniel Addis ◽

Henrik Møller ◽

Mina Youssef ◽

...

Keyword(s):

Prostate Cancer ◽

Cohort Study ◽

Prostate Specific Antigen ◽

Outcome Measures ◽

Androgen Deprivation Therapy ◽

Gleason Score ◽

Biochemical Recurrence ◽

Specific Antigen ◽

Androgen Deprivation ◽

Related Gene

ObjectivesTo determine whetherETS-related gene(ERG) expression can be used as a biomarker to predict biochemical recurrence and prostate cancer-specific death in patients with high Gleason grade prostate cancer treated with androgen deprivation therapy (ADT) as monotherapy.MethodsA multicentre retrospective cohort study identifying 149 patients treated with primary ADT for metastatic or non-metastatic prostate cancer with Gleason score 8–10 between 1999 and 2006. Patients planned for adjuvant radiotherapy at diagnosis were excluded. Age at diagnosis, ethnicity, prostate-specific antigen and Charlson-comorbidity score were recorded. Prostatic tissue acquired at biopsy or transurethral resection surgery was assessed for immunohistochemical expression ofERG. Failure of ADT defined as prostate specific antigen nadir +2. Vital status and death certification data determined using the UK National Cancer Registry. Primary outcome measures were overall survival (OS) and prostate cancer specific survival (CSS). Secondary outcome was biochemical recurrence-free survival (BRFS).ResultsThe median OS of our cohort was 60.2 months (CI 52.0 to 68.3).ERGexpression observed in 51/149 cases (34%). Multivariate Cox proportional hazards analysis showed no significant association betweenERGexpression and OS (p=0.41), CSS (p=0.92) and BRFS (p=0.31). Cox regression analysis showed Gleason score (p=0.003) and metastatic status (p<1×10-5) to be the only significant predictors of prostate CSS.ConclusionsNo significant association was found betweenERGstatus and any of our outcome measures. Despite a limited sample size, our results suggest thatERGdoes not appear to be a useful biomarker in predicting response to ADT in patients with high risk prostate cancer.

Download Full-text

Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen

Cancer ◽

10.1002/1097-0142(20010601)91:11<2196::aid-cncr1249>3.0.co;2-# ◽

2001 ◽

Vol 91 (11) ◽

pp. 2196-2204 ◽

Cited By ~ 80

Author(s):

Thomas J. Sebo ◽

John C. Cheville ◽

Darren L. Riehle ◽

Christine M. Lohse ◽

V. Shane Pankratz ◽

...

Keyword(s):

Radical Prostatectomy ◽

Prostate Specific Antigen ◽

Surface Area ◽

Prostate Carcinoma ◽

Needle Biopsy ◽

Perineural Invasion ◽

Dna Ploidy ◽

Specific Antigen ◽

Biopsy Specimens ◽

Preoperative Serum

Download Full-text

Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis

Annals of Palliative Medicine ◽

10.21037/apm-19-414 ◽

2020 ◽

Vol 9 (4) ◽

pp. 1708-1717

Author(s):

Shuai Liu ◽

Xiao-Ying Wang ◽

Tian-Bao Huang ◽

Quan Niu ◽

Kai Yao ◽

...

Keyword(s):

Prostate Cancer ◽

Propensity Score ◽

Prostate Specific Antigen ◽

Gleason Score ◽

Local Treatment ◽

Specific Antigen ◽

Population Based ◽

High Gleason Score

Download Full-text

Performance characteristics of prostate-specific antigen density and biopsy primary Gleason score to predict biochemical failure in patients with intermediate prostate cancer who underwent radical prostatectomy

Cancer Management and Research ◽

10.2147/cmar.s190443 ◽

2019 ◽

Vol Volume 11 ◽

pp. 1133-1139

Author(s):

Chao Peng ◽

Jun Zhang ◽

Jian-quan Hou

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Prostate Specific Antigen ◽

Gleason Score ◽

Specific Antigen ◽

Biochemical Failure ◽

Performance Characteristics ◽

Prostate Specific Antigen Density

Download Full-text

Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial.

Journal of Clinical Oncology ◽

10.1200/jco.1997.15.4.1465 ◽

1997 ◽

Vol 15 (4) ◽

pp. 1465-1469 ◽

Cited By ~ 39

Author(s):

A V D'Amico ◽

R Whittington ◽

S B Malkowicz ◽

D Schultz ◽

J E Tomaszewski ◽

...

Keyword(s):

Prostate Cancer ◽

Adjuvant Therapy ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Gleason Score ◽

Multivariable Analysis ◽

Specific Antigen ◽

Radical Retropubic Prostatectomy ◽

Phase Iii ◽

Psa Failure

PURPOSE A multivariable analysis to evaluate the potential clinical and pathologic factors that predict for early biochemical failure in patients with pathologically organ-confined and margin-negative disease was performed to define patients who may benefit from adjuvant therapy. PATIENTS AND METHODS Three hundred forty-one prostate cancer patients treated with a radical retropubic prostatectomy between January 1989 and June 1995 and found to have pathologically organ-confined and margin-negative disease comprised the study population. A logistic regression multivariable analysis to evaluate the predictive value of the preoperative prostate-specific antigen (PSA) level, pathologic (prostatectomy) Gleason score, and pathologic stage on PSA failure occurring during the first postoperative year was performed. RESULTS Predictors of PSA failure during the first postoperative year in patients with pathologically organ-confined disease included pathologic Gleason score > or = 7 (P = .0007) and preoperative PSA level greater than 10 (P < .0001). Corresponding 3-year freedom-from-PSA-failure rates for these pathologic organ-confined patients with both, one, or neither of these factors were 60%, 75% to 84%, and 95%, respectively (P < .0001). CONCLUSION Prostate cancer patients with pathologically organ-confined and margin-negative disease and a preoperative PSA level greater than 10 ng/mL or a pathologic Gleason score > or = 7 have significant decrements in short-term PSA-failure-free survival. Therefore, these patients should be considered for adjuvant therapy in the setting of a phase III clinical trial.

Download Full-text